Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from JJ.

5 Dividend Kings For Generations Of Passive Income

These are five Dividend Kings, companies with 50+ years of dividend increases, covering recent developments, dividend safety, and valuation, so you can identify candidates for durable income that fit your goals.

AI came from tech, but the most advanced AI businesses are in every industry

AI came from tech, but the most advanced AI businesses are in every industry

Fortune’s AIQ 50 list of the most “mature” AI companies shows how different businesses are taking advantage of AI to meet their needs.

Why This Dividend King Still Stands Tall

Why This Dividend King Still Stands Tall

With a strong product portfolio and growth prospects in innovative medicines, this dividend stock is likely to maintain its 63-year streak of dividend increases.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Tylenol maker Kenvue blasts Trump administration's autism claim

The over-the-counter drug is a critical product for Kenvue.

These 2 Healthcare Stocks Are Even Better Bargain Buys Than UnitedHealth

As the healthcare sector lags broader markets, AbbVie’s innovation in immunology and Johnson & Johnson’s MedTech expansion make these dividend giants standout bargains at below-market valuations

J&J Commits $2 Billion To US Manufacturing Expansion Amid Threat Of Drug Tariffs

Johnson Johnson (NYSE:JNJ) is set to invest $2 billion in its North Carolina facilities, expanding its U.S. manufacturing operations. This move comes in response to potential drug import tariffs proposed by the Trump administration.

“Impressive value for guitarists seeking rich clean/overdrive tones and timeless distortion tones”: PRS Archon Classic Head review

The PRS Archon Classic runs the gamut from crystal cleans to classic crunch and hot-rodded high gain

inkl

Read news from The Economist, FT, and more,
with one subscription

2 Recession-Proof Dividend Stocks to Buy for the Second Half of 2025

2 Recession-Proof Dividend Stocks to Buy for the Second Half of 2025

These blue-chip stocks offer a rare combination of stability, resilience, and moderate growth.

Stock Of The Day: Breakout In Johnson & Johnson

Stock Of The Day: Breakout In Johnson & Johnson

Johnson Johnson (NYSE:JNJ) stalled out at resistance around the $165 level. There tends to be resistance at price levels that had previously been resistance. As you can see on the chart below, that's the case here. This level was also resistance in March.

Dow's J&J Surges; Why Its Report Is Also Bullish For Stryker, Medtronic, Boston Scientific

Dow's J&J Surges; Why Its Report Is Also Bullish For Stryker, Medtronic, Boston Scientific

Johnson & Johnson stock jumped Wednesday after the Dow health behemoth raised its guidance in the wake of a bullish second-quarter report.

Investors Business Daily

Tylenol parent Kenvue has a new CEO, and he has lots of work to do to mollify activist investors

Tylenol parent Kenvue has a new CEO, and he has lots of work to do to mollify activist investors

The company will likely focus on off-loading smaller beauty brands.

6 Stocks to Buy to Give Your Portfolio the Perfect Mix of Growth, Value, and Defense

6 Stocks to Buy to Give Your Portfolio the Perfect Mix of Growth, Value, and Defense

This blend of stocks may be the key to long-term success.

Build a Bulletproof Dividend Portfolio With These 5 Defensive Stocks

Build a Bulletproof Dividend Portfolio With These 5 Defensive Stocks

These defensive stocks pay reliable dividends.

2 Companies Now Have Credit Ratings Higher Than The U.S.

2 Companies Now Have Credit Ratings Higher Than The U.S.

The U.S. may have just lost its AAA rating — but at least there are still financially responsible U.S. companies left.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Top Biotech Halozyme Undercuts Its Breakout On Bad Medicare News

Halozyme Therapeutics shares tumbled Tuesday on a new Medicare approach to price negotiations for drugs that use additive products.

J&J Snack Foods Hits New 52-Week Low: Time to Buy?

Among the 96 Nasdaq stocks hitting new 52-week lows Tuesday was the New Jersey-based manufacturer of snack foods and frozen beverages. The small-cap stock hit its 10th new 52-week low over the past 12 months. Time to buy?

Investors Business Daily

CG Oncology Soars On Its Johnson & Johnson-Rivaling Cancer Drug

Shares of CG Oncology catapulted Monday after the biotech unveiled promising results for a J&J-rivaling bladder cancer treatment.

UnitedHealth spent $1.7 million on executive security last year, 4 times the corporate average. Experts expect the figure to keep climbing

UnitedHealth Group reported its executive security compensation months after the CEO of health insurance arm UnitedHealthcare was fatally shot in December.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Stock Market Tumbles On Nvidia Export Curbs, Fed Chief Powell, UnitedHealth: Weekly Review

The stock market sold off this week, with Nvidia AI chip export curbs, UnitedHealth guidance and Fed chief Jerome Powell's comments in focus.

Investors Business Daily

Stock Market Today: Dow Jones, S&P 500 Close Lower; But This Recent IPO Name Bolts Higher For 3rd Straight Day (Live Coverage)

Stocks showed weakness Tuesday with the major indexes closing lower. But a recent IPO name climbed for a third straight day.

Investors Business Daily

J&J Flexes Its Financial 'Bicep,' Hiking Guidance Despite Tariff Headwinds

Johnson & Johnson stock fell alongside the broader market, despite beating first-quarter calls and hiking its 2025 sales guidance.

Investors Business Daily

J&J Dives After Judge Tosses Out $10 Billion Talc-Based Bankruptcy Plan

Johnson & Johnson stock slumped Tuesday after a judge rejected its $10 billion proposal to settle thousands of talc-tied lawsuits.

3 Dividend Stocks to Buy for a Safe Haven in This Volatile Market

The consistency in their dividend payments makes them dependable stocks in a volatile market.

Investors Business Daily

Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out

Protagonist Therapeutics broke out Monday after the company's drug topped its rival from Bristol in a psoriasis study.

The Independent UK

Johnson & Johnson begins battle over baby powder’s ‘link to cancer’ in $10 billion case

Courts have rejected J&J’s two previous efforts to resolve the talc litigation

People

145,156 stories

Mark Zuckerberg

Robert F. Kennedy Jr

Christopher Lopez

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

310,833 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play